International Congress on Hormonal Steroids and Hormones and Cancer

Up-regulation of LRP16 mRNA by 17β-estradiol through activation of estrogen receptor α (ERα), but not ERβ, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report

W-D Han, Y-M Mu1, X-C Lu2, Z-M Xu2, X-J Li2, L Yu2, H-J Song, M Li1, J-M Lu1, Y-L Zhao and C-Y Pan1

Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, People’s Republic of China
1Department of Endocrinology, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, People’s Republic of China
2Department of Hematology, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, People’s Republic of China

(Requests for offprints should be addressed to Y-M Mu; Email: muyiming@btamail.net.cn)

Abstract

LRP16 is a novel gene cloned from lymphocytic cells, and its function is not known. The expression level of LRP16 mRNA was up-regulated by estrogen in breast cancer MCF-7 cells based on the computed aided serial analysis of gene expression (SAGE) analysis. In this study, we investigate the effect of 17β-estradiol (17β-E2) on the expression of LRP16 mRNA and the effects of overexpression of LRP16 on the proliferation of cultured MCF-7 cells and the possible mechanisms involved. The expression level of LRP16 mRNA induced by 17β-E2 was determined by Northern blot analysis. LRP16 promoter-controlled luciferase expression vector (pGL3-S0) was co-transfected with various nuclear receptors, including estrogen receptor α and β (ERα and ERβ), glucocorticoid receptor α (GRα), androgen receptor (AR) and peroxisome-proliferator activated receptor γ and α (PPARγ and PPARα) into COS-7 cells, and the relative luciferase activity was measured using Dual-luciferase report assay systems. The effect of overexpression of LRP16 on MCF-7 proliferation was examined by the Trypan Blue exclusion method, and the cell cycle was analyzed by flow cytometry. The expression levels of cyclin E, p53 and p21\textsuperscript{WAF1/CIP1} proteins were determined by Western blot analysis. The results showed (1) 17β-E2 induced a five- to eightfold increase in LRP16 mRNA levels in MCF-7 cells; (2) the relative luciferase activities in the COS-7 cells co-transfected by pGL3-S0 and ERα or AR were 7.8-fold and 11-fold respectively of those in the control cells transfected by pGL3-S0 alone; (3) overexpression of LRP16 stimulated MCF-7 cell proliferation, and the numbers of cells in the S-phase of the cell cycle in cells transfected with LRP16 increased about 10% compared with the control cells; and (4) cyclin E levels were much higher in cells with overexpression of LRP16 than in the control cells, while the expression levels of p53 and p21\textsuperscript{WAF1/CIP1} were not different between the two groups of cells. From these results we concluded that estrogen up-regulates the expression level of LRP16 mRNA through activation of ERα and that overexpression of LRP16 promotes MCF-7 cell proliferation probably by increasing cyclin E.

Endocrine-Related Cancer (2003) 10 217–224
Introduction

Estrogen has very important effects on normal growth and differentiation in the mammary gland. Breast cancer development and progression are directly related to the effects of estrogen. The cloning of estrogen receptor alpha (ERα) from a breast cancer cell line, MCF-7, led to a greater understanding of its role in mediating the effects of estrogen (Green et al. 1986). ERα, as a transcription factor, binds to estrogen-response elements (EREs) in the promoter region of target genes (Tsai & O’Malley 1994) or interacts with proteins in other pathways (Batistuzzo de Medeiros et al. 1997, Gali-enard & Garcia 1997, Paech et al. 1997, Porter et al. 1999) to regulate the transcription of specific genes in estrogen-dependent cells. Numerous studies indicate that estrogen can induce and promote breast cancer and about 50% of primary breast cancers are ERα positive. For these reasons, decreasing estrogen production by aromatase inhibitors or blocking its action with anti-estrogens, e.g. tamoxifen and raloxifene, are the main treatments for ERα-positive tumors (Gradishar & Jordan 1997, Santen & Harvey 1999, Ali & Coombes 2000, Santen 2002). In addition to the direct effects of ERα as a nuclear transcription factor on breast cancer cells, there is growing evidence that estrogen has a proliferative effect on breast cancer cells via the regulation of various polypeptide growth factors, including insulin, insulin-like growth factor, transforming growth factor α (TGFα) and TGFβ (Knabbe et al. 1987, Bates et al. 1988, Osborne et al. 2001), growth factor receptors or other signaling molecules (Huynh et al. 1996). ERα can also directly or indirectly through growth factors activate phosphatidylinositol-3-kinase and mitogen-activated protein kinase pathways to regulate cell proliferation (Kato et al. 1995, Simoncini et al. 2000, Santen et al. 2002b).

LRP16 is a novel gene which was cloned from human lymphocyte cells by our group in 1999 using restriction length genomic scanning (RLGS), and then the cDNA was isolated using the rapid amplification of cDNA end (RACE) technique (GenBank Accession No. AF202922) (Yu et al. 2000). LRP16 contains an open reading frame for 325 amino acids. The expression of LRP16 mRNA was significantly increased in MCF-7 cells cultured with 17β-estradiol (17β-E2) compared with cells cultured without 17β-E2. Thus we hypothesized that LRP16 may be a downstream gene of the ERs including ERα and ERβ, and may contribute to MCF-7 cell proliferation after activation by ERs. In this study, we investigated the expression level of LRP16 mRNA in cultured MCF-7 cells, the regulation of the luciferase activity driven by LRP16 promoter and various nuclear receptors, and the effects of overexpression of LRP16 on MCF-7 cell proliferation.

Materials and methods

Materials

The vectors including pGL3-Basic, pRL-SV40, pGL3-CMV and pGEM-T-easy, Dual-luciferase report assay 1000 system, PCR product extraction kit, plasmid purification kit and probe DNA labeling reagents were purchased from Promega. Nuclear receptor expression vectors including ERβ, ERα, glucocorticoid receptor α (GRα), androgen receptor (AR) and peroxisome-proliferator activated receptor γ and α (PPARγ and PPARα) were kindly donated by Dr Hajime Nawata from Kyushu University of Japan. The transfection reagent SuperFect was purchased from Qiagen (Hilden, Germany). 17α-Estradiol, testosterone, dexamethasone and fenofibrate were purchased from Sigma (St Louis, MO, USA). Troglitazone was obtained from Sankyo Pharmaceuticals (Tokyo, Japan). All the above mentioned compounds were dissolved in dimethyl sulfoxide (DMSO), and the final concentration of DMSO in the cell growth medium was 0.1% (v/v). LA Taq DNA polymerase and various restriction enzymes were purchased from Takara (Otsu, Shiga, Japan). Fetal calf serum (FCS), Dulbecco’s modified Eagle’s medium (DMEM), proteinase K, RNA extraction reagent Trizol and G418 were purchased from Gibco BRL (Grand Island, NY, USA). Superscript II RNase H- reverse transcriptase was purchased from Invitrogen (Carlsbad, CA, USA). [α-32P]dCTP was purchased from YaHui Chemical Co. (Beijing, China). All antibodies, including anti-human cyclin E, p53, p21WAF1/CIP1 and β-actin used for the Western blot analysis and the chemiluminescence luminol reagent were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell culture

The COS-7 cell line and human breast cancer MCF-7 cells were purchased from ATCC (Rockville, MD, USA). COS-7 cells were maintained in DMEM supplemented with 10% FCS and 100 U/ml penicillin-streptomycin, and MCF-7 cells were maintained in DMEM supplemented with 10% FCS, 2 mM l-glutamine, 10 mg/ml bovine insulin and 100 U/ml penicillin-streptomycin in a humid atmosphere with 5% CO2 at 37 °C.

Northern blot analysis

To study the time- and dose-dependent effects of 17β-E2 on the expression level of LRP16 mRNA in MCF-7 cells, the cells were treated with various concentrations of 17β-E2, from 10−6 M to 10−4 M, for 48 h, or were treated with 10−4 M 17β-E2 for 3 to 48 h. An equal volume of DMSO was added to the cultured MCF-7 cells as control. Total RNAs were prepared by the acid guanidium thiocyanate-phenol
chloroform method using Trizol purchased from Gibco BRL. Twenty micrograms total RNA were electrophoresed through a 1% agarose gel containing formaldehyde and were transferred to a Hybond N+ membrane (Amersham). The membrane was hybridized with 32P-labeled LRP16 cDNA probe in 5 ml hybridization buffer containing 50% deionized formamide, 0.5 × SSPE, 0.5 × Denhardt’s solution, 0.5% sodium dodecyl sulfate (SDS), and 1 mg salmon sperm DNA (Sigma). After hybridization overnight at 50 °C, the membrane was washed according to the manufacturer’s instructions and exposed to BioMax-MS film (Eastman Kodak) for 2 days at −70 °C.

**Plasmid construction and luciferase analysis**

An LRP16 promoter fragment about 2.6 kb upstream from the translation start site was generated from genomic DNA of mononuclear cells from a healthy adult by PCR. The sequences of sense and antisense primers to amplify this fragment were 5′-GAGCTTCCGCGCTTGCTTGAACATGG-3′ and 5′-AAGCTTCCCCACTGGACTCTATT-3′ respectively. The PCR products were subcloned into pGEM-T-easy vector and were sequenced to ensure that no misincorporated mutations were introduced into the PCR products during amplification. The reporter recombinant pGL3-S0, was generated by inserting the promoter fragment into the SacI and HindIII sites of pGL3-basic vector. Transfection was performed using SuperFect reagents according to the manufacturer’s instructions. Briefly, COS-7 cells were seeded in 35 mm dishes (1 × 104 each dish) 12 h prior to transfection, and they were co-transfected with 1 µg pGL3-S0 and 1 µg of various nuclear receptors including ERα, ERβ, GRα, AR, PPARγ or PPARα. One hundred nanograms renilla luciferase control vector pRL-SV40 (as an internal standard) were added to each dish to assess the transfection efficiency. After 12 h of transfection, 10,000 M of various ligands including 17β-E2, testosterone, dexamethasone, troglitazone or fenofibrate were added to the dishes. On the next day of transfection, the cells were lysed and harvested using the Dual-luciferase reporter assay system and the luciferase activity was analyzed using Lumat LB 9507. The promoter activity was expressed as fold increase in luciferase activity normalized for renilla luciferase activity (termed relative luciferase activity).

**Construction of LRP16 expression vector and stable transfection**

The entire coding region of LRP16 was generated from cDNA extracted from MCF-7 cells by RT-PCR using the sense/antisense (5′-TTGGCGGAGAGCGCGTCGGC-3′/5′-CGGGGCGGAGGGAAAGAG-3′) primers, the design of which was based on our previous reported sequence (Han et al. 2001a,b). The PCR products were subcloned into pGEM-T-easy vector and sequenced to ensure that no misincorporated mutations were introduced into PCR products during amplification. The full coding region of LRP16, which was a 1134 bp fragment, was digested with KpnI and BamHI from pGEM-LRP16 and was inserted into the same sites of the pcDNA3.1 vector. The construction was confirmed by enzymatic digestion, and was sequenced to verify the correct reading frame. The construct (pcDNA-LRP16) was transfected into MCF-7 cells by the SuperFect transfection reagent. Two days after transfection, the cells were treated with G418 at 1 mg/ml for 3 weeks and then were continuously cultured with 0.5 mg/ml G418. For a cell proliferation assay, the cells transfected with LRP16 or empty vector were plated onto 24-well plates at 1 × 104 cells/well in the culture medium and the medium was changed every 2 days. After washing with PBS two times, the cells were trypsinized and then counted by the Trypan Blue exclusion method using a hemocytometer every 24 h for 5 days.

**Western blot analysis**

The expression of the cell cycle-related proteins including p53, p21WAF1/CIP1 and cyclin E, and β-actin were examined by Western blot analysis, as described previously (Mu et al. 2001), using specific antibodies. The MCF-7 cells transfected with LRP16 or empty vector were washed with PBS and lysed with SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride supplemented with 0.2 trypsin inhibitory units/ml aprotinin, 0.7 µg/ml pepstatin, and 1 mg/ml leupeptin). The samples were sonicated for a few seconds to shear the DNA and reduce the viscosity. Twenty micrograms protein were mixed with an equal volume of 2 × electrophoresis buffer, then boiled for 3 min. The samples were electrophoresed on a 12% SDS-polyacrylamide gel, and proteins were transferred to a Hybond-P, polyvinylidene difluoride membrane (Amersham Pharmacia Biotech, Little Chalfont, Bucks, UK). Blots were rinsed in Tris-buffered saline–0.1% Tween-20 and blocked with 4% BSA overnight at 4 °C. The blots were incubated with mouse antihuman p53 (1:1000), goat antihuman p21WAF1/CIP1 (1:1000), rabbit antihuman cyclin E (1:1000), or mouse antihuman β-actin (1:200) antibodies for 1 h at room temperature. After washing with Tris-buffered saline–0.1% Tween-20 three times, blots were probed with horseradish peroxidase-labeled antimouse, antigoat or antirabbit IgG (1:1000) in blocking buffer. Proteins were detected using a chemiluminescence luminol reagent, and the bands were visualized by autoradiography.

**Statistical analysis**

For the cell proliferation assay, experiments were performed in triplicate, and the results were expressed as the mean ± S.D.
of three independent experiments. A statistical analysis was performed using Statview software. All data were evaluated for paired variables to compare two groups. \( P < 0.05 \) was considered to be statistically significant.

**Results**

17\( \beta \)-E\(_2\) increases the expression level of LRP16 mRNA in MCF-7 cells

MCF-7 cells were treated with various concentrations of 17\( \beta \)-E\(_2\) from \( 10^{-9} \) to \( 10^{-6} \) M/l for 48 h, then the total RNA was extracted and the expression level of LRP16 mRNA was determined by Northern blot analysis. As shown in Fig. 1, the expression levels of LRP16 mRNA in the cells treated with various concentrations of 17\( \beta \)-E\(_2\) were two- to threefold higher than those in control cells. The time course for the effect of \( 10^{-6} \) M/l 17\( \beta \)-E\(_2\) on the expression level of LRP16 mRNA was investigated over a 48-h time period. The significant increase in LRP16 mRNA levels was observed as early as 3 h after addition of 17\( \beta \)-E\(_2\). The expression levels of LRP16 mRNA in the cells treated with 17\( \beta \)-E\(_2\) for 3 to 48 h were five- to eightfold higher than those in the cells before treatment with 17\( \beta \)-E\(_2\). This stimulatory effect of 17\( \beta \)-E\(_2\) was neither dose- nor time-dependent.

17\( \beta \)-E\(_2\) up-regulates LRP16 mRNA through activation of ER\( \alpha \)

To investigate whether or not the elevation of LRP16 mRNA by 17\( \beta \)-E\(_2\) was associated with activation of ERs, and whether various other nuclear receptors including AR, GR\( \alpha \), PPAR\( \gamma \) and PPAR\( \alpha \) also regulate the transcription of LRP16 mRNA, we made the LRP16 promoter expression construct, pGL3-S\(_0\), and determined the luciferase activity. As shown in Fig. 2, the luciferase activity in the cells co-transfected with pGL3-S\(_0\) and ER\( \alpha \) or AR were 11- and 7.8-fold higher, respectively, than that in the cells transfected with pGL3-S\(_0\) alone. Other nuclear receptors including ER\( \beta \), GR\( \alpha \), PPAR\( \gamma \) and PPAR\( \alpha \) had either no or only a slight effect on the luciferase activity driven by the LRP16 promoter. These results indicate that 17\( \beta \)-E\(_2\) may up-regulate LRP16 mRNA by activation of ER\( \alpha \), but not ER\( \beta \), and that LRP16 mRNA transcription was specifically regulated by ER\( \alpha \) and AR.

Overexpression of LRP16 promotes MCF-7 cell proliferation

To determine whether overexpression of LRP16 promotes MCF-7 cell proliferation, the entire coding region of LRP16 was cloned into pcDNA3.1 vector under the control of the cytomegalovirus (CMV) promoter and the resulting plasmid was transfected into MCF-7 cells. The empty vector was used as a negative control. The cells were then treated with 1 mg/ml G418 for 3 weeks. All of the MCF-7 parental cells were killed by G418 within this period. In response to overexpression of LRP16, we observed profound alterations in cell proliferation. As shown in Fig. 3, cell proliferation was markedly promoted after LRP16 transfection. On the third day of observation, the number of cells transfected with LRP16 was about twofold greater than the control cells. The effects of overexpression of LRP16 on cell differentiation were analyzed by flow cytometry. Overexpression of LRP16 induced a decrease of about 10% in cell numbers in G\(_0\)/G\(_1\) phase, and an increase of about 10% in cell numbers in S phase.

Overexpression of LRP16 increases cyclin E

The expression levels of p53, p21\(^{WAF1/CIP1}\) and cyclin E were measured by Western blot analysis to determine if these proteins, which play important roles in the G\(_0\)/G\(_1\) checkpoint control of cell differentiation, were changed by overexpression of LRP16. As shown in Fig. 4, the expression levels of p53 and p21\(^{WAF1/CIP1}\) were not different in the cells showing
overexpression of LRP16 compared with control cells, while cyclin E was much higher in the cells with overexpression of LRP16 compared with control cells.

Discussion

We cloned LRP16 from lymphocytes with the purpose of finding a leukemia relapse related gene, but there was no difference between patients diagnosed with acute myeloid leukemia and relapsed patients in LRP16 mRNA expression levels as determined by semi-quantitative RT-PCR (Han et al. 2002). Computer-aided SAGE analysis indicated that LRP16 might be important for breast cancer cell proliferation because 17β-E2 induced a significant increase in LRP16 mRNA in MCF-7 cells. In the present study, we investigated the regulation of LRP16 mRNA by 17β-E2 in cultured
Han et al.: Effects of LRP16 on MCF-7 cells

**Figure 4** Expression of p53, p21(WAF1/CIP1), cyclin E and β-actin determined by Western blot analysis. Proteins were extracted from the cells transfected with LRP16 or empty vector (control) and a Western blot analysis was performed with the specific antibodies as indicated.

MCF-7 cells, the effects of ERs on LRP16 transcription, and the possible mechanisms involved. The MCF-7 breast cancer cell line is an estrogen-dependent cell line and expresses a high level of intracellular ERα. Consistent with the results of SAGE analysis, we demonstrated that 17β-E2 up-regulated LRP16 mRNA expression levels in MCF-7 cells, and this effect was observed as early as 3 h after addition of 17β-E2. After 3 h treatment, the expression of LRP16 mRNA was at a persistently high level and there was no further change over 48 h, indicating that the effect of 17β-E2 was rapid and that regulation might be at the transcription level of the LRP16 gene. All of the concentrations of 17β-E2, from 10^{-9} to 10^{-6} M/L, employed in this study presented similar stimulatory effects, indicating that 17β-E2 was a strong regulator for LRP16 transcript; concentrations lower than 10^{-6} M/L 17β-E2 might have a dose-dependent effect as has been shown for cell proliferation in MCF-7 cells. Further studies are needed to clarify these points.

A number of studies have demonstrated that breast cancer is a hormone-dependent multistep process that can be induced by a variety of compounds and mechanisms, i.e. hormones, chemicals, radiation and viruses, in addition to or in combination with genetic factors (Russo et al. 2002). Although estrogens have been shown to play a central role in breast cancer development, their carcinogenicity on human breast epithelial cells has not yet been clearly demonstrated. Perhaps the most important pathway for the action of estrogen on the target cells is mediated via ERα and/or ERβ, which function as ligand-activated transcription factors regulating gene expression at specific EREs in the DNA (Katzenellenbogen & Katzenellenbogen 2000). Our study demonstrated that LRP16 transcription was specifically regulated by ERα, but not by ERβ, since the luciferase activity driven by LRP16 promoter was significantly up-regulated by co-transfection with ERα, while co-transfection with ERβ had little effect on the activity. These results indicate that LRP16 is a specific downstream gene of ERα, which may play an important role in breast cancer proliferation. Even though many functions have been suggested for ERβ in the breast (Gustafsson & Warner 2000, Knowlden et al. 2000, Speirs & Kerin 2000, Warner et al. 2000), no clear picture has emerged about its role in breast cancer. Previous studies have demonstrated that when ovariectomized mice were implanted s.c. with pellets composed of estrogen and progestrone, mammary glands in the ERβ-/- mice were indistinguishable from those of similarly treated wild-type mice, indicating that ERβ is not necessary for estrogen-induced proliferation of the mammary gland (Palmieri et al. 2002).

Accumulating evidence indicates that androgens and the AR modulate the development and progression of breast cancer; however, the precise role and actions remain poorly defined. AR is expressed in approximately 35–75% of breast cancers (Ellis et al. 1989, Kuenen-Boumeester et al. 1992). The number of AR-positive samples and the level of AR mRNA were significantly higher among the cancer samples than among normal samples. The expression level of both AR gene and AR protein in nuclei was found to be positively correlated with tumor invasiveness (Brys et al. 2002). Our study showed that AR had a similar effect as ERα in the up-regulation of LRP16 transcription. But the significance of this up-regulative effect on LRP16 is as yet unknown. Further studies are needed to determine the mechanisms of action of the effects of ERα and AR on LRP16 transcription may be direct by binding to their response elements in the LRP16 promoter or indirect by activation of growth factors or other pathways; (2) the stimulatory effect of androgen on LRP16 transcription may be mediated by AR or by aromatization of androgen to estrogen and then binding to ERα. Computer-aided analysis showed that there are at least nine imperfectly palindromic estrogen response elements and 3 1/2ERE(n)x SP1 sequences (Safe 2001) in the 2.6 kb LRP16 promoter employed in this study.

Up-regulation of LRP16 transcription by ERα in MCF-7 cells implied that this gene may contribute to cell proliferation. This hypothesis was demonstrated in the present study. Overexpression of LRP16 promoted MCF-7 cell proliferation and this effect might be induced by increased cyclin E protein which is an important protein for G1/S checkpoint control of cell differentiation. Overexpression of cyclin E has been demonstrated to promote MCF-7 cell proliferation by stimulating G1/S transition (Sgambato et al. 1997, Huang et al. 2000, Chappelli et al. 2001).

The understanding of how estrogen induces breast cancer development and progress is important for creating strategies and targets for breast cancer prevention and treatment. In this study we demonstrated, for the first time, that LRP16 is a new downstream gene of ERα and AR. The stimulative effect of overexpression of LRP16 on MCF-7 cell proliferation indicates that LRP16 is a new candidate for investigating the mechanism of breast cancer development. Blocking
the effect of LRP16 via its antisense oligonucleotide or in other ways may also provide a novel therapy for estrogen-dependent diseases.

Acknowledgements

We are grateful to Dr Hajime Nawata from Kyushu University of Japan for his kind donation of the nuclear receptor expression vectors. This work was supported by the National Natural Science Foundation of China (No. 30200095).

References


Safe S 2001 Transcriptional activation of genes by 17beta-estradiol through estrogen receptor–Sp1 interactions. Vitamins and
Han et al.: Effects of LRP16 on MCF-7 cells

Hormones – Advances in Research and Applications 62 231–252.
Santen RJ 2002 To block estrogen’s synthesis or action: that is the question. Journal of Clinical Endocrinology and Metabolism 87 3007–3012.
Santen RJ & Harvey HA 1999 Use of aromatase inhibitors in breast cancer. Endocrine-Related Cancer 6 75–92.